MARINUS PHARMACEUTICALS INC (MRNS) Forecast, Price Target & Analyst Ratings

NASDAQ:MRNS • US56854Q2003

Current stock price

0.55 USD
+0 (+0.09%)
At close:
0.5491 USD
0 (-0.16%)
Pre-Market:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MARINUS PHARMACEUTICALS INC (MRNS).

Forecast Snapshot

Consensus Price Target

Price Target
$1.09
+ 97.82% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Mar 11, 2025
Period
Q4 / 2024
EPS Estimate
-$0.34
Revenue Estimate
10.802M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
73.85%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$1.09
Upside
+ 97.82%
From current price of $0.55 to mean target of $1.09, Based on 13 analyst forecasts
Low
$0.30
Median
$0.79
High
$2.10

Price Target Revisions

1 Month
-60.28%
3 Months
-87.45%

Price Target Summary

13 Wall Street analysts provided a forecast for the next 12 months for MRNS. The average price target is 1.09 USD. This implies a price increase of 97.82% is expected in the next year compared to the current price of 0.55.
The average price target has been revised downward by 87.45% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

MRNS Current Analyst RatingMRNS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

MRNS Historical Analyst RatingsMRNS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
73.85%
MRNS was analyzed by 13 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about MRNS.
In the previous month the buy percentage consensus was at a similar level.
MRNS was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2024-11-14Cantor FitzgeraldReiterate Overweight -> Overweight
2024-11-14HC Wainwright & Co.Reiterate Neutral -> Neutral
2024-11-13D. Boral CapitalMaintains Buy -> Buy
2024-10-25TD CowenDowngrade Buy -> Hold
2024-10-25Cantor FitzgeraldMaintains Overweight -> Overweight
2024-10-25RBC CapitalMaintains Sector Perform -> Sector Perform
2024-10-25JefferiesDowngrade Buy -> Hold
2024-10-25HC Wainwright & Co.Downgrade Buy -> Neutral
2024-10-24EF HuttonMaintains Buy -> Buy
2024-10-24JMP SecuritiesDowngrade Market Outperform -> Market Perform
2024-10-17EF HuttonMaintains Buy -> Buy
2024-10-11EF HuttonMaintains Buy -> Buy
2024-09-30EF HuttonInitiate Buy
2024-09-24Cantor FitzgeraldReiterate Overweight -> Overweight
2024-09-23JMP SecuritiesReiterate Market Outperform -> Market Outperform
2024-09-23OppenheimerUpgrade Perform -> Outperform
2024-09-16Cantor FitzgeraldReiterate Overweight -> Overweight
2024-09-09Cantor FitzgeraldReiterate Overweight -> Overweight
2024-08-14Ladenburg ThalmannDowngrade Buy -> Neutral
2024-08-14HC Wainwright & Co.Reiterate Buy -> Buy
2024-06-18Truist SecuritiesMaintains Buy -> Buy
2024-06-18HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-09HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-07HC Wainwright & Co.Maintains Buy -> Buy
2024-04-17Truist SecuritiesMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Mar 11, 2025
Period
Q4 / 2024
EPS Estimate
-$0.34
Revenue Estimate
10.802M
Revenue Q2Q
50.24%
EPS Q2Q
54.28%
Number of Analysts
9

Next Earnings Revisions

Revenue (1 Month)
1.09%
Revenue (3 Months)
-9.47%
EPS (1 Month)
-13.44%
EPS (3 Months)
37.61%

Next Earnings Summary

MRNS is expected to report earnings on 3/11/2025. The consensus EPS estimate for the next earnings is -0.34 USD and the consensus revenue estimate is 10.80M USD.
The next earnings revenue estimate has been revised downward by 9.47% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2024 - 2032

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
MRNS revenue by date.MRNS revenue by date.
15.35M
792.44%		25.48M
65.99%		30.989M
21.62%		35.628M
14.97%		56.168M
57.65%		62.524M
11.32%		104.63M
67.34%		129.77M
24.03%		124.36M
-4.17%		126.33M
1.58%		133.7M
5.83%		135.66M
1.47%
EBITDA
YoY % growth
MRNS ebitda by date.MRNS ebitda by date.
-95.09M
-40.64%		-112.37M
-18.17%		-130.934M
-16.52%		N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
MRNS ebit by date.MRNS ebit by date.
-95.45M
-40.49%		-112.79M
-18.17%		-131.485M
-16.58%		-108.238M
17.68%		-27.857M
74.26%		-21.089M
24.29%		15.585M
173.90%		37.813M
142.62%		35.817M
-5.28%		34.959M
-2.40%		39.484M
12.94%		39.008M
-1.21%
Operating Margin
MRNS operating margin by date.MRNS operating margin by date.
-621.82%-442.66%-424.30%-303.80%-49.60%-33.73%14.90%29.14%28.80%27.67%29.53%28.75%
EPS
YoY % growth
MRNS eps by date.MRNS eps by date.
-2.69
-4.26%		-3.28
-21.93%		-2.63
19.82%		-2.11
19.91%		-0.50
76.03%		-0.30
40.74%		0.13
143.19%		0.17
30.23%		-0.01
-106.06%		-0.09
-800.00%		0.04
144.44%		0.14
250.00%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-0.34
54.28%		-0.20
70.00%		-0.18
70.25%		-0.13
69.04%		-0.07
78.14%
Revenue
Q2Q % growth		10.802M
50.24%		10.567M
37.61%		11.623M
44.28%		12.87M
50.68%		16.998M
57.36%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-17.438M
50.79%		-11.92M
66.72%		-9.933M
67.20%		-8.147M
61.35%		-4.152M
76.19%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

MRNS Yearly Revenue VS EstimatesMRNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
MRNS Yearly EPS VS EstimatesMRNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
23.56%
EPS Next 5 Year
15.60%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
24.44%
Revenue Next 5 Year
31.95%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

MARINUS PHARMACEUTICALS INC / MRNS Forecast FAQ

Can you provide the average price target for MARINUS PHARMACEUTICALS INC stock?

13 analysts have analysed MRNS and the average price target is 1.09 USD. This implies a price increase of 97.82% is expected in the next year compared to the current price of 0.55.

Can you provide the upcoming earnings date for MARINUS PHARMACEUTICALS INC?

MARINUS PHARMACEUTICALS INC (MRNS) will report earnings on 2025-03-11, after the market close.

Can you provide the consensus estimates for MARINUS PHARMACEUTICALS INC next earnings?

The consensus EPS estimate for the next earnings of MARINUS PHARMACEUTICALS INC (MRNS) is -0.34 USD and the consensus revenue estimate is 10.80M USD.

What is the number of analysts for MRNS stock?

The number of analysts covering MARINUS PHARMACEUTICALS INC (MRNS) is 13.